In a clinical trial of patients with early-stage inflammatory RA, the mean pain visual analog scores (VAS 0–100) decreased by nearly 40 points in patients using the IL-6 inhibitor to lizumab, suggesting that anti-inflammatory therapy can effectively reduce the inflammatory pain response in RA (43). This evidence concerns the gene IL6 and rheumatoid arthritis.